Every year, 5 million people die from blood loss, primarily during surgery. Surgeons require better hemostatic agents to reduce the number of deaths from hemorrhaging.[1]
Gelatin is the hemostatic of choice
Gelatin can absorb up to 40 times its weight in blood or fluids and can expand up to 200% in vivo[2]. Currently, gelatin-based hemostatic products are widely used to stop bleeding and promote clotting in the operating theatre, mainly in the form of sponges, strips, powder, or nanofibers. However, endotoxins present within these gelatins can contribute to risk of inflammation.
A versatile and ultra-low endotoxin solution that can help to reduce the risk of adverse reaction
The X-Pure® range of gelatins and collagens with low endotoxin levels reduce the risk of inflammatory reactions. X-Pure gelatin can be effectively applied to create hemostatic products with adapted irregular geometries, foaming and expanding when applied to the site of bleeding [3].
Our expert team can advise you on the most suitable gelatin for your specific biomedical application. All Rousselot Biomedical gelatins provide biocompatibility, biodegradability, and batch-to-batch consistency.
| Gelatins | Type | Endotoxin Level (EU/g)1 | Gel Strength*(g)2 | Application |
|---|---|---|---|---|
| X-Pure® 10P | Acid porcine skin gelatin | Extremely low endotoxin levels ≤10 | 300-400 | Cardiovascular system, lymphatic system, cerebrospinal fluid |
| X-Pure® 10B | Lime bovine bone gelatin | Extremely low endotoxin levels ≤10 | 240-360 | Cardiovascular system, lymphatic system, cerebrospinal fluid |
| Quali-Pure™ 250P | Acid porcine skin gelatin | Specification upon request | 250 | Hemostatic devices |
| Quali-Pure™ 300P | Acid porcine skin gelatin | Specification upon request | 300 | Hemostatic devices |
| Quali-Pure™ 300P HV | Acid porcine skin gelatin | Specification upon request | 300 | Hemostatic devices |
Rousselot Biomedical gelatins meet international requirements for hemostats
- Full and documented traceability up to the farm (ISO 22442- 2:2020)
- Validated viral inactivation (ISO 22442-3:2007)
- Controlled purity and endotoxin levels
- Batch-to-batch consistency
- Good Manufacturing Practices (IPEC-PQG GMP 2017)
- Excellent absorption capacity: gelatin can absorb up to 40 times its weight in blood, and can expand by 200%
- Biocompatible and biodegradable
- Gelatin-based products reach fast and efficient hemostasis
- Easily grindable for syringe application, for instance, if you want to combine gelatin with thrombin
- Suitable for both human and veterinary hemostatic applications.
References:
[1] Fortune Insights. Hemostatic Agents Market to reach US$ 5,441.5 Mn by 2025, at a CAGR of 6.4% | Exclusive Report by Fortune Business Insights [Internet]. GlobeNewswire News Room. 2019 [cited 24 March 2021]. Available from: https://www.globenewswire.com/news-release/2019/06/24/1872780/0/en/Hemostatic-Agents-Market-to-reach-US-5-441-5-Mn-by-2025-at-a-CAGR-of-6-4-Exclusive-Report-by-Fortune-Business-Insights.html
[2] Sundaram, C.P. and Keenan, A.C., 2010. Evolution of hemostatic agents in surgical practice.Indian journal of urology: IJU: journal of the Urological Society of India, 26(3), p.374.
[3] Ribeiro, A.M., Meneses, A.C. and Neumann, I.A., 2018. Polymeric nanoparticles and sponges in the control and stagnation of bleeding and wound healing. In Design of Nanostructures for Versatile Therapeutic Applications (pp. 189-219). William Andrew Publishing.